A biotech company
driving new genome
with 5 FTE, founded in
2016, operating in DE.
Funds raised: $450K
Funds sought: $500K
Burn rate: $40K per
Annual revenue: N/A
Hajime Sakai (CEO)
Thomas Fox (Cornell
THRIVE SVG Partners
Bill Provine (DISI)
NAPIGEN, INC. Hajime Sakai
200 Powder Mill Rd. President & CEO
Wilmington, DE 19803 302-644-5464
One line pitch: Opening a new business horizon with our one-of-a-kind
mitochondrial CRISPR genome editing in agriculture, industrial biotech
and human/animal healthcare.
Business Summary: We develop and offer next-generation solutions
through our mitochondrial CRISPR to produce a wide range of products
such as producing hybrid wheat seeds, which are long awaited in
agriculture, instantly increasing yield >15%, with potential value of $23B
p.a. In addition, we intend to create long-term business opportunities
in industrial biotech and human/animal healthcare business.
Management: (Board of Directors) Hajime Sakai (CEO), Ganesh Kishore
(Chair), Roger Wyse and Jay Keasling
Customer Problem/Opportunity: No reliable method of producing
hybrid wheat seeds available / no efficient production of certain
biomolecules in yeast cultures / no good approaches to fix
mitochondrial mutations in animals and humans to cure diseases.
Product/Service: Provide new genetics and method of creating hybrid
wheat for AG / production platform in yeast / remedy of diseases.
Target Market: World-wide
Customers: Major AG seed companies (Bayer, Corteva, Syngenta, KWS
etc.) for hybrid wheat business.
Sales/Marketing Strategy: TBD
Business Model: IP Licensing and co-development of hybrid wheat with
an AG seed company, and other applications through partnership etc.
Competition: Hybrid Wheat production with male sterile plants induced
by chemicals (Syngenta, Staaten Union).
Competitive Advantage: Hybrid wheat _Chemical approaches are
expensive and difficult to apply due to the short window of time for
good results. Our approach provides a low cost solution with robust
Financials: (5-year projections) Revenues are expected in 2020 ($500K),
2021 ($1MM), 2022 (>$2MM) through IP licensing and contract R&D,
and in 2023 acquisition possibility with >$60MM.